BRPI1008155A2 - método para tratar câncer - Google Patents

método para tratar câncer

Info

Publication number
BRPI1008155A2
BRPI1008155A2 BRPI1008155A BRPI1008155A BRPI1008155A2 BR PI1008155 A2 BRPI1008155 A2 BR PI1008155A2 BR PI1008155 A BRPI1008155 A BR PI1008155A BR PI1008155 A BRPI1008155 A BR PI1008155A BR PI1008155 A2 BRPI1008155 A2 BR PI1008155A2
Authority
BR
Brazil
Prior art keywords
treat cancer
cancer
treat
Prior art date
Application number
BRPI1008155A
Other languages
English (en)
Inventor
Beverly Teicher
Edmond J Lavoie
Stevem Schmid
Original Assignee
Genzyme Corp
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42077313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1008155(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Univ Rutgers filed Critical Genzyme Corp
Publication of BRPI1008155A2 publication Critical patent/BRPI1008155A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1008155A 2009-01-30 2010-01-29 método para tratar câncer BRPI1008155A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14888109P 2009-01-30 2009-01-30
US24087309P 2009-09-09 2009-09-09
PCT/US2010/022625 WO2010088544A1 (en) 2009-01-30 2010-01-29 Methods to treat cancer

Publications (1)

Publication Number Publication Date
BRPI1008155A2 true BRPI1008155A2 (pt) 2016-03-08

Family

ID=42077313

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008155A BRPI1008155A2 (pt) 2009-01-30 2010-01-29 método para tratar câncer

Country Status (19)

Country Link
US (1) US20120004235A1 (pt)
EP (1) EP2391364A1 (pt)
JP (1) JP2012516849A (pt)
KR (1) KR20110122141A (pt)
CN (1) CN102395368A (pt)
AR (1) AR075346A1 (pt)
AU (1) AU2010208042A1 (pt)
BR (1) BRPI1008155A2 (pt)
CA (1) CA2749204A1 (pt)
CL (1) CL2011001850A1 (pt)
CO (1) CO6410302A2 (pt)
EA (1) EA201101140A1 (pt)
IL (1) IL213919A0 (pt)
MX (1) MX2011008069A (pt)
NZ (1) NZ593849A (pt)
PE (1) PE20120112A1 (pt)
SG (1) SG173454A1 (pt)
TW (1) TW201038578A (pt)
WO (1) WO2010088544A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2403856B1 (en) 2009-03-06 2012-12-19 Rutgers, The State University of New Jersey Methylenedioxybenzo [i]phenanthridine derivatives used to treat cancer
JP2019515025A (ja) 2016-04-04 2019-06-06 ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー トポイソメラーゼ毒
CN108690034A (zh) * 2018-01-12 2018-10-23 兰州大学 一种氟化苯并萘啶酮类衍生物、制备方法及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (pt) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
AU1236401A (en) 1999-10-29 2001-05-14 Rutgers, The State University Of New Jerey Heterocyclic cytotoxic agents
WO2003041653A2 (en) * 2001-11-14 2003-05-22 Rutgers, The State University Cytotoxic agents
MXPA04004606A (es) * 2001-11-14 2004-09-10 Univ Rutgers Venenos de topoisomerasa solubilizados.
US6992089B2 (en) * 2002-08-09 2006-01-31 Rutgers, The University Of New Jersey Nitro and amino substituted topoisomerase agents
AU2003265406A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted topoisomerase agents

Also Published As

Publication number Publication date
WO2010088544A1 (en) 2010-08-05
CO6410302A2 (es) 2012-03-30
MX2011008069A (es) 2011-09-06
WO2010088544A8 (en) 2011-07-28
CN102395368A (zh) 2012-03-28
JP2012516849A (ja) 2012-07-26
NZ593849A (en) 2014-02-28
TW201038578A (en) 2010-11-01
EA201101140A1 (ru) 2012-03-30
EP2391364A1 (en) 2011-12-07
SG173454A1 (en) 2011-09-29
CA2749204A1 (en) 2010-08-05
KR20110122141A (ko) 2011-11-09
US20120004235A1 (en) 2012-01-05
IL213919A0 (en) 2011-07-31
PE20120112A1 (es) 2012-02-27
CL2011001850A1 (es) 2012-08-31
AR075346A1 (es) 2011-03-23
AU2010208042A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
BR112014006324A2 (pt) método para tratar hcv
BR112013033720A2 (pt) método para tratar eczema
BR112014007603A2 (pt) métodos de tratamento do câncer
BR112014032105A2 (pt) método para o tratamento de câncer
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
BR112012005594A2 (pt) tratamento de câncer
BR112013007678A2 (pt) método para tratamento de doenças alérgicas
DK2707030T3 (da) Cancerbehandlinger
BR112014006702A2 (pt) método para tratar osteoporose
BRPI1011226A2 (pt) métodos para tratar condições relacionadas ao cabelo
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BRPI1010874A2 (pt) composição para o tratamento de câncer de próstata
BRPI1008253A2 (pt) Metoso para tratar biomassa
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BR112014012880A2 (pt) tratamento imunogênico do câncer
BR112013008528A2 (pt) métodos para tratar psoríase
BRPI1013361A2 (pt) método para evitar e tratar hipermeabilidade.
BRPI0908715A2 (pt) métodos para tratamento da psoríase
BR112014009785A2 (pt) método para tratar ou reduzir efp
BR112013011659A2 (pt) métodos de tratamento do câncer
BRPI1007459A2 (pt) método para produção de manômeros olefínicos
BR112014011008A2 (pt) método de quantificação de tratamento de câncer
BRPI0921679A2 (pt) composto útil para tratar celulite
BR112013028890A2 (pt) composições e métodos para o tratamento de câncer
BRPI0822264A2 (pt) Dapsona para tratar rosácea

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.